{"body":"<ol><li>WHO ARV dosing generic tool [website]. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/www.who.int\/groups\/antiretroviral-drug-optimization\">https:\/\/www.who.int\/groups\/antiretroviral-drug-optimization<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Annex 1. Summary of product characteristics. Tivicay. Amsterdam: European Medicines Agency; 2020 (<a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tivicay-epar-product-information_en.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tivicay-epar-product-information_en.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>FDA approves drug to treat infants and children with HIV. Washington (DC): United States Food and Drug Administration; 2020 (<a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-treat-infants-and-children-hiv\">https:\/\/www.fda.gov\/news-events\/ press-announcements\/fda-approves-drug-treat-infants-and-children-hiv?utm_campaign=061220_PR_United States Food and Drug Administration%20Approves%20Drug%20to%20Treat%20Infants%20and%20Children%20with%20HIV&amp;utm_medium=email&amp;utm_source=Eloqua<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Safety of and immune response to dolutegravir in HIV-1 infected infants, children, and Adolescents. Bethesda (MD): ClinicalTrials.gov; 2020 (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302847\">https:\/\/clinicaltrials.gov\/ct2\/show\/ NCT01302847<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Turkova A. Dolutegravir-based ART is superior to NNRTI\/PI-based ART in children and adolescents. 28th Conference on Retroviruses and Opportunistic Infections, virtual, 3 June-3 November 2021 (<a href=\"https:\/\/www.croiconference.org\/abstract\/dolutegravir-based-art-is-superior-to-nnrti-pi-based-art-in-\">https:\/\/www.croiconference.org\/abstract\/dolutegravir-based-art-is-superior-to-nnrti-pi-based-art-in-children-and-adolescents<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Dolutegravir tablet for oral suspension. Washington (DC): United States Food and Drug Administration; 2020 (<a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/pepfar\/214521PI.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/pepfar\/214521 PI. pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Jacobs TG, Svensson EM, Musiime V, Rojo\u00a0P,\u00a0Dooley KE, Mcllleron H. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV\/TB co-infection: a systematic review. J Antimicrob Chemother. 2020;75:3433-57.<\/li>&#13;\n\t<li>Teppler H, Thompson K, Chain A, Mathe M, Nachman S, Clarke D. Crushing of raltegravir (RAL) chewable tablets for administration in infants and young children. International Workshop on HIV Pediatrics, Paris, France, 21-22 July 2017.<\/li>&#13;\n\t<li>GENVOYA\u00ae (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use. Washington (DC): United States Food and Drug Administration; 2017 (<a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207561s013lbl.pdf\">https:\/\/ www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207561s013lbl.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Paediatric ARV dosing dashboard [website]. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/www.who.int\/groups\/antiretroviral-drug-optimization\">https:\/\/www.who.int\/groups\/antiretroviral-drug-optimization<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>World Health Organization prequalification [website]. Geneva: World Health Organization; 2021 (<a href=\"http:\/\/apps.who.int\/prequal\">http:\/\/apps.who.int\/prequal<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Quick reference guide for PEPFAR Database; interactive database for antiretroviral (ARV) drugs tentatively approved or approved that are eligible for procurement. Washington (DC): United States Food and Drug Administration; 2021 (<a href=\"https:\/\/www.fda.gov\/InternationalPrograms\/PEPFAR\/ucm119231.htm\">https:\/\/www.fda.gov\/ InternationalPrograms\/PEPFAR\/ucm119231.htm<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Sourcing and management of health products [website]. Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2021 (<a href=\"https:\/\/www.theglobalfund.org\/en\/sourcing-management\/quality-assurance\/medicines\">https:\/\/www.theglobalfund.org\/en\/sourcing-management\/quality-assurance\/medicines<\/a>, accessed 1 June 2021.<\/li>&#13;\n\t<li>REYATAZ\u00ae (atazanavir) oral powder. Washington (DC): United States Food and Drug Administration; 2018 (<a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021567s042,206352s007lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/ label\/2018\/021567s042,206352s007lbl.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Cotton MF, Liberty A, Torres-Escobar I, Gonzalez-Tome MI, Lissens J, Zaru L et al. Safety and efficacy of atazanavir powder and ritonavir in HIV-1-infected infants and children from 3 months to &lt;11 years of age: the PRINCE-2 Study. Pediatr Infect Dis J. 2018;37:e149-56.<\/li>&#13;\n\t<li>A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART. Bethesda (MD):\u00a0<a href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/a>; 2020 (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02259127\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02259127<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>WHO, Interagency Task Team (IATT) on Prevention of HIV Infection in Pregnant Women, Mothers and their Children, UNICEF). Fact sheet on lopinavir and ritonavir (LPV\/R) oral pellets: 40 mg\/10 mg per capsule bottle pack containing 120 capsules. Geneva: World Health Organization; 2015 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/193543\">https:\/\/apps.who.int\/iris\/handle\/10665\/193543<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Lopinavir\/ritonavir 40 mg\/10 mg pellets and granules and 100\/25 mg tablets. ARV Procurement Working Group; 2020 (<a href=\"https:\/\/www.arvprocurementworkinggroup.org\/lpv-r-supply\">https:\/\/www.arvprocurementworkinggroup.org\/lpv-r-supply<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>19.\u00a0Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A et al. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. AIDS. 2012;26:1795-800.<\/li>&#13;\n\t<li>ISENTRESS\u00ae (raltegravir) film-coated tablets, for oral use, ISENTRESS\u00ae HD (raltegravir) film-coated tablets, for oral use, ISENTRESS\u00ae (raltegravir) chewable tablets, for oral use, ISENTRESS\u00ae (raltegravir) for oral suspension. Washington (DC): United States Food and Drug Administration; 2020 (<a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022145s042,203045s016,205786s008lblrpl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/ label\/2020\/022145s042,203045s016,205786s008lblrpl.pdf<\/a>, accessed ~1 June 2021).<\/li>&#13;\n\t<li>Bollen PDJ, Moore CL, Mujuru HA, Makumbi S, Kekitiinwa AR, Kaudha E et al. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. Lancet HIV. 2020;7:e533-44.<\/li>&#13;\n\t<li>Rabie H, Denti\u00a0P,\u00a0Lee J, Masango M, Coovadia A, Pillay S et al. Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. Lancet HIV. 2018:S2352-3018(18)30293-5.<\/li>&#13;\n\t<li>Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. The Lancet. 2016 Feb 6;387(10018):566-73.<\/li>&#13;\n\t<li>ARV Procurement Working Group [website]. ARV Procurement Working Group; 2021 (<a href=\"https:\/\/arvprocurementworkinggroup.org\/en\">https:\/\/arvprocurementworkinggroup.org\/en<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Global Accelerator for Paediatric Formulations Network (GAP-f) [website]. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/www.who.int\/initiatives\/gap-f\">https:\/\/www.who.int\/initiatives\/gap-f<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>The 2021 optimal formulary and limited-use list for antiretroviral drugs for children. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240023529\">https:\/\/www.who.int\/publications\/i\/item\/9789240023529<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Meeting report: Paediatric Antiretroviral Drug Optimization (PADO) Meeting 4. Geneva: World Health Organization; 2018 (<a href=\"https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/pado4.pdf?sfvrsn=26d\">https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/pado4.pdf?sfvrsn=26d4169c_5<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Penazzato M, Townsend CL, Rakhmanina N, Cheng\u00a0Y,\u00a0Archary M, Cressey TR et al. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. Lancet HIV. 2019;6:e623-31.<\/li>&#13;\n<\/ol>","title":"References","nid":647,"vid":2818,"created":1632929988,"changed":1632930282,"field_content_type":{"tid":1,"name":"Content","class":"content"}}